Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention Following an Acute Knee Injury
NCT05204836 · University of Calgary · PHASE1 · terminated · last registry update 2025-12-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Recruitment stopped due to funding shortage. The scope of the original study increased beyond what had been budgeted in the grant that funded it, and follow-up funding attempts were not successful.” | – | Registry record, University of Calgary |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FDPS within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Also stopped (terminated): City of Hope Medical Center, zoledronic acid (NCT01409811)
- 2026-11-04Results posted on the registry: University of Nebraska, Capecitabine + Fluorouracil (NCT03073785)
- 2026-10-27Results posted on the registry: Nami Safai Haeri, Denosumab + Zoledronic Acid (NCT05666310)
- 2026-06-30Results posted on the registry: Alliance for Clinical Trials in Oncology, ixazomib + lenalidomide (NCT02516423)
- 2026-06-30Also stopped (terminated): Alliance for Clinical Trials in Oncology, ixazomib + lenalidomide (NCT02516423)
- 2026-06-05Also stopped (withdrawn): University Hospital, Rouen, a drug against FDPS (NCT04253340)
- 2026-06-04Also stopped (withdrawn): University of Pittsburgh, Romosozumab + Alendronate (Fosamax) (NCT06973109)
- 2026-04-23Results posted on the registry: University of Alabama at Birmingham, DMAB Discontinuation and Switching (NCT04177940)
- 2026-02-27Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Bisphosphonates Combined with Vancomycin + Vancomycin (NCT07435051)
- 2025-12-16Results posted on the registry: Karen Klahr Miller, MD, Romosozumab Prefilled Syringe + Placebo (NCT04779216)
- 2025-10-29Results posted on the registry: Massachusetts General Hospital, Denosumab + Placebo (NCT04087096)
- 2025-09-24Results posted on the registry: Northwestern University, Romosozumab + Alendronate (NCT04708886)
- 2025-07-09Phase 3 first posted: Prince of Wales Hospital, Shatin, Hong Kong, Denosumab (Prolia) + Zoledronic acide (Aclasta) (NCT07056478)
- 2025-06-19Phase 3 first posted: Shenzhen Salubris Pharmaceuticals Co., Ltd., SAL056 (56.5μg) + Alendronate (NCT07028320)
- 2025-06-08Results posted on the registry: Institut Bergonié, Sirolimus combined with CP, MT and ZA (NCT02517918)
- 2024-12-13Results posted on the registry: University Hospital, Ghent, Alendronate Effervescent Oral Tablet (NCT04403698)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision